Galcanezumab (Emgality®). HTA ID: 20052

Assessment Status Assessment process complete
HTA ID 20052
Drug Galcanezumab
Brand Emgality®
Indication For the prophylaxis of migraine in adults who have at least four migraine days per month.
Assessment Process
Rapid review commissioned 02/12/2020
Rapid review completed 13/01/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of galcanezumab (Emgality®) on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations March 2022.